PROCEPT BioRobotics Q3 EPS $(0.51) Beats $(0.53) Estimate, Sales $35.10M Beat $33.09M Estimate
Portfolio Pulse from mahesh@benzinga.com
PROCEPT BioRobotics (NASDAQ:PRCT) reported Q3 losses of $(0.51) per share, beating the analyst consensus estimate of $(0.53) by 3.77%. The company's quarterly sales were $35.10 million, surpassing the analyst consensus estimate of $33.09 million by 6.08%. This represents a 72.50% increase over sales of $20.35 million in the same period last year.
November 01, 2023 | 9:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PROCEPT BioRobotics reported better than expected Q3 earnings and sales, which could positively impact its stock price.
PROCEPT BioRobotics reported Q3 earnings and sales that beat analyst estimates. This is generally seen as positive news by investors and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100